Evidence map›Paper›PMID 38311182›Full record

ArticleMetabolic engineering2024

LipidSIM: Inferring mechanistic lipid biosynthesis perturbations from lipidomics with a flexible, low-parameter, Markov modeling framework.

Chenguang Liang, Sue Murray, Yang Li, Richard Lee, Audrey Low, Shruti Sasaki, Austin W T Chiang, Wen-Jen Lin, Joel Mathews, Will Barnes and 1 more

Open access · greenAbstract read
In one paragraph

Article in Metabolic engineering, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Chenguang LiangDepartment of Bioengineering, University of California, La Jolla, CA, 92093, USA.
Sue MurrayIonis Pharmaceuticals, Inc., Carlsbad, CA, 92010, USA.
Yang LiIonis Pharmaceuticals, Inc., Carlsbad, CA, 92010, USA.
Richard LeeIonis Pharmaceuticals, Inc., Carlsbad, CA, 92010, USA.
Audrey LowIonis Pharmaceuticals, Inc., Carlsbad, CA, 92010, USA.
Shruti SasakiIonis Pharmaceuticals, Inc., Carlsbad, CA, 92010, USA.
Austin W T ChiangDepartment of Pediatrics, University of California, La Jolla, CA, 92093, USA.
Wen-Jen LinGraduate Institute of Biomedical Science, China Medical University, Taichung 404333, Taiwan.
Joel MathewsIonis Pharmaceuticals, Inc., Carlsbad, CA, 92010, USA.
Will BarnesIonis Pharmaceuticals, Inc., Carlsbad, CA, 92010, USA.
Nathan E LewisDepartment of Bioengineering, University of California, La Jolla, CA, 92093, USA; Department of Pediatrics, University of California, La Jolla, CA, 92093, USA. Electronic address: nlewisres@ucsd.edu.
Ionis Pharmaceuticals (United States) · USUniversity of California San Diego · USChina Medical University · TWLa Jolla Bioengineering Institute · US

Funding

Unraveling the mammalian secretory pathway through systems biology and algorithm developmentR35GM119850 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LEWIS, NATHAN ENOCH · 2016 to 2025
$4.3M
NIGMS NIH HHS R35 GM119850
6 · The paper itself

Abstract

Lipid metabolism is a complex and dynamic system involving numerous enzymes at the junction of multiple metabolic pathways. Disruption of these pathways leads to systematic dyslipidemia, a hallmark of many pathological developments, such as nonalcoholic steatohepatitis and diabetes. Recent advances in computational tools can provide insights into the dysregulation of lipid biosynthesis, but limitations remain due to the complexity of lipidomic data, limited knowledge of interactions among involved enzymes, and technical challenges in standardizing across different lipid types. Here, we present a low-parameter, biologically interpretable framework named Lipid Synthesis Investigative Markov model (LipidSIM), which models and predicts the source of perturbations in lipid biosynthesis from lipidomic data. LipidSIM achieves this by accounting for the interdependency between the lipid species via the lipid biosynthesis network and generates testable hypotheses regarding changes in lipid biosynthetic reactions. This feature allows the integration of lipidomics with other omics types, such as transcriptomics, to elucidate the direct driving mechanisms of altered lipidomes due to treatments or disease progression. To demonstrate the value of LipidSIM, we first applied it to hepatic lipidomics following Keap1 knockdown and found that changes in mRNA expression of the lipid pathways were consistent with the LipidSIM-predicted fluxes. Second, we used it to study lipidomic changes following intraperitoneal injection of CCl

Indexed as

DyslipidemiasNon-alcoholic Fatty Liver DiseaseHumansKelch-Like ECH-Associated Protein 1Lipid MetabolismLipidomicsLipidsNF-E2-Related Factor 2Kelch-Like ECH-Associated Protein 1LipidsNF-E2-Related Factor 2

Identifiers

PMID38311182
PMCPMC11163374
OpenAlexW4391485172

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.